Chinese Journal of Tissue Engineering Research ›› 2015, Vol. 19 ›› Issue (49): 8010-8014.doi: 10.3969/j.issn.2095-4344.2015.49.024

Previous Articles     Next Articles

Establishment of rat models of chronic rejection after heterotopic tracheal transplantation and the relationship with interleukin-17

Wu Dong1, Li Xiao-jun2, Liu Mao-lin3, Wang Jian-jun1, Zhai Wei1   

  1. 1Department of Cardiothoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China; 2Department of Cardiothoracic Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong Province, China; 3Dongfeng General Hospital of Shiyan City, Shiyan 442000, Hubei Province, China
  • Received:2015-09-07 Online:2015-11-30 Published:2015-11-30
  • Contact: Zhai Wei, M.D., Associate professor, Department of Cardiothoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
  • About author:Wu Dong, Studying for master’s degree, Department of Cardiothoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China Li Xiao-jun, Master, Physician, Department of Cardiothoracic Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong Province, China Wu Dong and Li Xiao-jun contributed equally to this article
  • Supported by:

    the National Natural Science Foundation of China, No. 30700767; the Foundation of the Ministry of Education of China for Returned Overseas Chinese Scholars, No. 2008890; the Natural Science Foundation of Hubei Province of China, No. 2013CFB088

Abstract:

BACKGROUND: Obliterative bronchiolitis is one of the major complications of lung transplantation. Establishing a stable and reliable animal model is a prerequisite to the study of obliterative bronchiolitis.
OBJECTIVE: To establish rat models of chronic rejection after heterotopic tracheal transplantation and investigate the effect of interleakin-17 in this model. 
METHODS: After making donor/recipient pairs according to body weight, Wistar and Sprague-Dawley rats were 
randomly divided into 2 groups (n=30): Wistar (donor)→SD (recipient) group and SD (donor)→SD (recipient) group. The trachea was embedded by recipient’s cervical subcutaneous tissue. Tracheal tissue was harvested at different time points for histopathological analysis. The indicators including epithelial loss, lymphocyte count, the ratio of anuclear chondrocyte number to total chondrocyte number and the expression level of interleukin-17 in the transplanted trachea were determined.
RESULTS AND CONCLUSION: Recipients from these two groups all survived. At the 7th,14th and 28th days after transplantation, there was significant difference in lymphocyte count between these two groups (P < 0.05). At the 14th and 28th days after transplantation, there was significant difference in the ratio of anuclear chondrocyte number to total chondrocyte number between these two groups (P < 0.05). At the 7th, 14th and 28th days after transplantation, the degree of epithelial loss of rats in Wistar (donor)→SD (recipient) group was respectively > 40%, 100%, 100%, however, there was no obvious loss in the SD (donor)→SD (recipient) group. At the 28th day after transplantation, the incidence of obliterative bronchiolitis was 100% in Wistar (donor)→SD (recipient) group, however, no occlusion was observed in rats from the SD (donor)→SD (recipient) group. At the 28th day after transplantation, the expression level of interleukin-17 in Wistar (donor)→SD (recipient) group was significantly higher than that in the SD (donor)→SD (recipient) group (P < 0.05) These results demonstrate that Wistar (donor)→SD (recipient) rat models of chronic rejection after heterotopic tracheal transplantation were successfully established in this study, which provide a platform for the study of bronchiolitis obliterans. Interleukin-17 may play an important role in this field.
 

CLC Number: